Introducing NEW Drug Monitoring Assays - Nivolumab (Opdivo®)
Posted by Brandon Savela on Mar 24th 2017
This message is to inform you about some new developments concerning our ImmunoGuide product range.
We are pleased to present our new Nivolumab (Opdivo®) kit development:
Nivolumab (Opdivo®) (mAb-based) (Cat# IG-AB113) ELISA is now available.
The solid phase (MTP) is coated by a highly specific monoclonal antibody directed against Nivolumab. The drug Nivolumab (Opdivo®) is a fully human IgG4 monoclonal antibody that binds specifically to programmed death-1 (PD-1), a negative regulatory receptor expressed by activated T and B lymphocytes. Binding of Nivolumab to the PD-1 receptor blocks its interaction with the ligands, PDL1 and PD-L2, thereby attenuating PD-1–mediated inhibition of the immune response, including the antitumor immune response. The specificity of this testsystem is achieved by using a monoclonal antibody named "NY-11C3" for the coating of the microtiter plate. This antibody is specific for Nivolumab only and does not cross react with other PD-1 catchers. This enzyme immunoassay is for the specific determination of free Nivolumab in serum and plasma.
Anti-Nivolumab (Opdivo®) (Cat# IG-BB113) ELISA (for the measurement of anti-Nivolumab).
The potential development of anti-drug antibodies (ADA) may interfere with the drug's efficacy. This is mainly judged by observing the relapse of signs and symptoms of disease and can necessitate dose-escalation. The ImmunoGuide Antibody to Nivolumab ELISA Kit can be used for the measurement of free antibodies against this drug. It does not detect such antibodies which already are bound to the drug.
View our full selection of ImmunoGuide Drug and anti-Drug assays
